These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23507470)

  • 1. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.
    Karuturi M; Hosing C; Fanale M; Medeiros LJ; Alousi AM; de Lima MJ; Qazilbash MH; Kebriaei P; Younes A; Khouri I; Andersson BS; Champlin R; Anderlini P; Popat U
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):991-4. PubMed ID: 23507470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
    Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
    Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
    Hartmann S; Plütschow A; Mottok A; Bernd HW; Feller AC; Ott G; Cogliatti S; Fend F; Quintanilla-Martinez L; Stein H; Klapper W; Möller P; Rosenwald A; Engert A; Hansmann ML; Eichenauer DA
    Am J Hematol; 2019 Nov; 94(11):1208-1213. PubMed ID: 31396979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
    Eichenauer DA; Hartmann S
    Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
    Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
    Klekawka T; Balwierz W; Brozyna A; Chaber R; Dadela-Urbanek A; Koltan A; Kwasnicka J; Mitura-Lesiuk M; Muszynska-Roslan K; Przybyszewski B; Ruranska I; Smalisz K; Mizia-Malarz A; Stachowicz-Stencel T; Stolarska M; Wziatek A; Zielezinska K; Skoczen S
    Pediatr Hematol Oncol; 2021 Oct; 38(7):609-619. PubMed ID: 33734010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
    Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
    Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
    Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
    Farrell K; McKay P; Leach M
    Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.